Safety of long­‑acting β2­‑agonists: a little bit of history. Dr. Paul O’Byrne in an interview with Dr. Roman Jaeschke: part 1

Safety of long‑acting β2‑agonists: a little bit of history. Dr. Paul O’Byrne in an interview with Dr. Roman Jaeschke: part 1

Paul O’Byrne, Roman Jaeschke

DOI: 10.20452/pamw.3667

Published online: November 30, 2016
CC BY-NC-SA 4.0

Full-text article available only as a pdf file for download

Download PDF

Most cited

Lippi G, Wong J, Henry B

Pol Arch Intern Med. 2020, Vol. 130, No. 4: 304–309; DOI: 10.20452/pamw.15272

Staszel T, Zapała B, Polus A, Sadakierska‑Chudy A, Kieć‑Wilk B, Stępień E, Wybrańska I, Chojnacka M, Dembińska‑Kieć A

Pol Arch Intern Med. 2011, Vol. 121, No. 10: 361–367; DOI: 10.20452/pamw.1093

Kasińska M, Drzewoski J

Pol Arch Intern Med. 2015, Vol. 125, No. 11: 803–813; DOI: 10.20452/pamw.3156

Chou R

Pol Arch Intern Med. 2009, Vol. 119, No. 7-8: 469–477; DOI: 10.20452/pamw.741

Edrees H, Paine L, Feroli E, Wu A

Pol Arch Intern Med. 2011, Vol. 121, No. 4: 101–108; DOI: 10.20452/pamw.1033

Lippi G, Sanchis-Gomar F, Henry B

Pol Arch Intern Med. 2023, Vol. 133, No. 4: 16402; DOI: 10.20452/pamw.16402

Yao Q, Wang P, Wang X, Qie G, Meng M, Tong X, Bai X, Ding M, Liu W, Liu K, Chu Y

Pol Arch Intern Med. 2020, Vol. 130, No. 5: 390–399; DOI: 10.20452/pamw.15312